Halcygen Pharmaceuticals (ASX:HGN) has arranged to acquire Mayne Pharma International from Hospira Australia for $15 million.
As part of the deal, Halcygen has agreed to share a portion of the unit’s earnings with Hospira, so long as certain sales targets are met, the company said.
MPI is expected to report revenues of $63.2 million and an EBITDA of $31.2 million for calendar year 2009.
Halcygen today offered its existing shareholders the opportunity to participate in a share purchase plan at a cost of 20 cents per share.
Join the CIO Australia group on LinkedIn. The group is open to CIOs, IT Directors, COOs, CTOs and senior IT managers.